Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-08-02
2011-08-02
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C435S005000, C530S333000
Reexamination Certificate
active
07988975
ABSTRACT:
The invention involves a synthetic peptide derived from HIV-1 virus gp41 having sequencewhere X615is F or G, a method of preparing the synthetic peptide, a composition and a kit containing the synthetic peptide, and use of the synthetic peptide in immunoassays for the detection of infections caused by HIV-1 viruses.
REFERENCES:
patent: 4879212 (1989-11-01), Wang et al.
patent: 2004/0072267 (2004-04-01), Rieunier et al.
patent: 0 326 490 (1989-08-01), None
patent: WO 98/45323 (1998-10-01), None
Gnann, J. W., et al., 1987, Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus, J. Virol. 61(8):2639-2641.
Gadelle Stephane
Rieunier Francois
Bio-Rad Pasteur
Jacobson & Holman PLLC
Parkin Jeffrey
LandOfFree
Modified HIV-1 group M cyclic gp41 peptides and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified HIV-1 group M cyclic gp41 peptides and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified HIV-1 group M cyclic gp41 peptides and their use in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2765238